AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31283756 — intervention group
Group type: EXPERIMENTAL
Intervention: J-Tpeakc (parameter from second FDA study)
Number of subjects: 44
Study 31283756 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Tr10c to Tr100c in logistic regression model
Number of subjects: 44
Study 28598453 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Glyceryl Trinitrate (GTN)
Number of subjects: 90
Study 28598453 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Nifedipine
Number of subjects: 90
Study 28598453 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 90
Study 25646201 — intervention group
Group type: EXPERIMENTAL
Intervention: 20‐mL/kg isotonic saline bolus
Number of subjects: 126
Study 25646201 — intervention group
Group type: COMPARATOR
Intervention: Control (no fluid bolus)
Number of subjects: 126
Study 23410851 — intervention group
Group type: EXPERIMENTAL
Intervention: Family economic empowerment intervention (matched children savings accounts, financial management workshops, mentorship)
Number of subjects: 297
Study 23410851 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 297
Study 21429094 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch users
Number of subjects: 191
Study 21429094 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available patches
Number of subjects: 191
Study 21429094 — intervention group
Group type: COMPARATOR
Intervention: Non-patch users
Number of subjects: 191
Study 20110012 — intervention group
Group type: COMPARATOR
Intervention: Once-daily extended-release (ER) pramipexole 0.75 mg
Number of subjects: 72
Study 20110012 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ER pramipexole 0.375 mg (fasted state)
Number of subjects: 72
Study 20110012 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ER pramipexole 0.375 mg (fed state)
Number of subjects: 72
Study 20110012 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-state ER pramipexole 0.375 to 4.5 mg (fasted state)
Number of subjects: 72
Study 20110012 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-state ER pramipexole 4.5 mg
Number of subjects: 72
Study 17827952 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of infliximab with immunosuppressives at onset
Number of subjects: 0
Study 17827952 — intervention group
Group type: COMPARATOR
Intervention: Current standard approach (step-up strategy)
Number of subjects: 0
Study 15176536 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral refeeding
Number of subjects: 28
Study 15176536 — intervention group
Group type: COMPARATOR
Intervention: Jejunal tube refeeding
Number of subjects: 28
Study 15176536 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 11814156 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-session group intervention
Number of subjects: 148
Study 11814156 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 148
Study 9601682 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HT2A receptor promoter polymorphism ‐1438G/A in patients with mood disorders
Number of subjects: 95
Study 9601682 — intervention group
Group type: COMPARATOR
Intervention: Healthy Japanese controls
Number of subjects: 95
Study 8017593 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% pethidine
Number of subjects: 0
Study 8017593 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% pethidine
Number of subjects: 0
Study 8017593 — intervention group
Group type: COMPARATOR
Intervention: 0.5% prilocaine
Number of subjects: 0
Study 2684554 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment after 1 night
Number of subjects: 39
Study 2684554 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment after 14 nights
Number of subjects: 39
Study 2684554 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment after 42 nights
Number of subjects: 39
Study 2684554 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 39
Study 1102646 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiheart antibody (AHA) in high titer
Number of subjects: 257
Study 1102646 — intervention group
Group type: COMPARATOR
Intervention: No AHA
Number of subjects: 257
Study 1102646 — intervention group
Group type: EXPERIMENTAL
Intervention: Rise in titer to viral agents
Number of subjects: 257
Study 30987619 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional metacarpal splint (FMS)
Number of subjects: 58
Study 30987619 — intervention group
Group type: COMPARATOR
Intervention: Ulnar gutter splint (UGS)
Number of subjects: 58
Study 28274253 — intervention group
Group type: EXPERIMENTAL
Intervention: Namilumab 150 mg
Number of subjects: 24
Study 28274253 — intervention group
Group type: EXPERIMENTAL
Intervention: Namilumab 300 mg
Number of subjects: 24
Study 28274253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28274253 — intervention group
Group type: EXPERIMENTAL
Intervention: Namilumab (150 and 300 mg combined)
Number of subjects: 24
Study 25567115 — intervention group
Group type: EXPERIMENTAL
Intervention: Anrukinzumab 200 mg
Number of subjects: 84
Study 25567115 — intervention group
Group type: EXPERIMENTAL
Intervention: Anrukinzumab 400 mg
Number of subjects: 84
Study 25567115 — intervention group
Group type: EXPERIMENTAL
Intervention: Anrukinzumab 600 mg
Number of subjects: 84
Study 25567115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 25567115 — intervention group
Group type: EXPERIMENTAL
Intervention: Anrukinzumab (all doses)
Number of subjects: 84
Study 25567115 — intervention group
Group type: COMPARATOR
Intervention: Anrukinzumab and Placebo
Number of subjects: 84
Study 23787775 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuine UMTS RF EMF exposure (1.75 W/kg for 30 min)
Number of subjects: 20
Study 23787775 — intervention group
Group type: COMPARATOR
Intervention: Sham condition (placebo)
Number of subjects: 20
Study 23787775 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 20
Study 21710265 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 kV
Number of subjects: 42
Study 21710265 — intervention group
Group type: COMPARATOR
Intervention: 120 kV
Number of subjects: 42
Study 18059046 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 0
Study 16469404 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (prednisolone 30 mg daily)
Number of subjects: 101
Study 16469404 — intervention group
Group type: COMPARATOR
Intervention: Antioxidant cocktail
Number of subjects: 101
Study 14506496 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/day of fish oil (containing approximately 450 mg eicosapentaenoic acid and 350 mg docosahexaenoic acid)
Number of subjects: 500
Study 14506496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 10684911 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (two 2-g doses)
Number of subjects: 1953
Study 10684911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1953
Study 10684911 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 1953
Study 8823580 — intervention group
Group type: EXPERIMENTAL
Intervention: Lodoxamide
Number of subjects: 20
Study 8823580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8823580 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 20
Study 1481177 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at 2 1/min
Number of subjects: 30
Study 1481177 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at 4 1/min
Number of subjects: 30
Study 1481177 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at 6 1/min
Number of subjects: 30
Study 1481177 — intervention group
Group type: COMPARATOR
Intervention: Baseline unburdened walk
Number of subjects: 30
Study 1481177 — intervention group
Group type: COMPARATOR
Intervention: Portable gas supply
Number of subjects: 30
Study 3970608 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 20
Study 3970608 — intervention group
Group type: COMPARATOR
Intervention: Electrolyte cardioplegia
Number of subjects: 20
Study 3970608 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 20
Study 29419785 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nutritional formula
Number of subjects: 14
Study 29419785 — intervention group
Group type: COMPARATOR
Intervention: Solid breakfast
Number of subjects: 14
Study 29419785 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid product
Number of subjects: 14
Study 26733410 — intervention group
Group type: EXPERIMENTAL
Intervention: SkQ1 1.55 µg/mL
Number of subjects: 91
Study 26733410 — intervention group
Group type: EXPERIMENTAL
Intervention: SkQ1 0.155 µg/mL
Number of subjects: 91
Study 26733410 — intervention group
Group type: COMPARATOR
Intervention: 0.0 µg/mL (placebo)
Number of subjects: 91
Study 24378998 — intervention group
Group type: EXPERIMENTAL
Intervention: Barostim therapy
Number of subjects: 1
Study 24378998 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical treatment
Number of subjects: 1
Study 22503105 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) therapy with prednisone, initiated at 0.05 mg/kg/d, adjusted to maintain a trough blood level of 5 to 10 ng/mL for 1 year.
Number of subjects: 37
Study 22503105 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) pulse cyclophosphamide (CTX) therapy with prednisone, initiated at 1 g/1.73 m(2) for a total dosage of 10 g/1.73 m(2) over 1 year.
Number of subjects: 37
Study 20489031 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib (900 mg) plus pravastatin
Number of subjects: 0
Study 20489031 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib (900 mg) plus rosuvastatin
Number of subjects: 0
Study 20489031 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib (900 mg) plus simvastatin
Number of subjects: 0
Study 20489031 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib (900 mg)
Number of subjects: 0
Study 20489031 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib alone and coadministered with statins
Number of subjects: 0
Study 18064444 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin
Number of subjects: 12
Study 18064444 — intervention group
Group type: COMPARATOR
Intervention: Cotinine/Nicotine
Number of subjects: 12
Study 16126119 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin+RSG 4 mg b.i.d.
Number of subjects: 38
Study 16126119 — intervention group
Group type: COMPARATOR
Intervention: metformin+placebo
Number of subjects: 38
Study 12198218 — intervention group
Group type: EXPERIMENTAL
Intervention: CAHP‐210 hemodialyzer with vancomycin infused during the last hour of dialysis
Number of subjects: 8
Study 12198218 — intervention group
Group type: COMPARATOR
Intervention: Post-haemodialysis administration of vancomycin 15 mg/kg
Number of subjects: 8
Study 9445320 — intervention group
Group type: EXPERIMENTAL
Intervention: rpro-UK (6 mg)
Number of subjects: 46
Study 9445320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 7621133 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% O2 in N2
Number of subjects: 5
Study 7621133 — intervention group
Group type: EXPERIMENTAL
Intervention: 16% O2 in N2
Number of subjects: 5
Study 7621133 — intervention group
Group type: COMPARATOR
Intervention: 21% O2 in N2 (normoxia)
Number of subjects: 5
Study 2495144 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) 1 hour exposure time
Number of subjects: 70
Study 2495144 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin-C (MMC) 0.5 hour exposure time
Number of subjects: 70
Study 2495144 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC)
Number of subjects: 70
Study 327955 — intervention group
Group type: EXPERIMENTAL
Intervention: Seventh-Day Adventists (strict vegetarians)
Number of subjects: 28
Study 327955 — intervention group
Group type: COMPARATOR
Intervention: General western diet
Number of subjects: 28
Study 6789350 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg orally)
Number of subjects: 0
Study 31881992 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder stimulation
Number of subjects: 770
Study 31881992 — intervention group
Group type: COMPARATOR
Intervention: Urinary catheterization
Number of subjects: 770
Study 29985014 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational Empowerment Photovoice (VEP) program
Number of subjects: 51
Study 29985014 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 51
Study 26918564 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-day buprenorphine taper
Number of subjects: 53
Study 26918564 — intervention group
Group type: EXPERIMENTAL
Intervention: 56-day buprenorphine taper
Number of subjects: 53
Study 25086842 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 2774
Study 25086842 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 2774
Study 23421088 — intervention group
Group type: EXPERIMENTAL
Intervention: Emdogain treatment
Number of subjects: 28
Study 23421088 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular open flap procedure)
Number of subjects: 28
Study 22958267 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient pulmonary rehabilitation
Number of subjects: 0
Study 22958267 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation
Number of subjects: 0
Study 22958267 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 17991267 — intervention group
Group type: EXPERIMENTAL
Intervention: CobraPLA
Number of subjects: 38
Study 17991267 — intervention group
Group type: COMPARATOR
Intervention: LMA Classic
Number of subjects: 38
Study 15640389 — intervention group
Group type: EXPERIMENTAL
Intervention: REX-albuterol treatment
Number of subjects: 0
Study 15640389 — intervention group
Group type: COMPARATOR
Intervention: REX-placebo
Number of subjects: 0
Study 15640389 — intervention group
Group type: COMPARATOR
Intervention: Unloaded controls
Number of subjects: 0
Study 11988606 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimulation
Number of subjects: 13
Study 9826114 — intervention group
Group type: COMPARATOR
Intervention: (+)-UH232, single doses of 80 to 180 mg
Number of subjects: 6
Study 7662761 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 35
Study 7662761 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 35
Study 2674821 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendazac lysine
Number of subjects: 53
Study 2674821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 71969 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (150 mg to 200 mg daily)
Number of subjects: 26
Study 71969 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (75 mg to 100 mg daily)
Number of subjects: 26
Study 71969 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 26
Study 71969 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 26
Study 30053042 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of AL-794
Number of subjects: 61
Study 30053042 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of AL-794
Number of subjects: 61
Study 30053042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 28684232 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (SS) with shoulder extension and internal rotation for 20 to 120 seconds
Number of subjects: 20
Study 28684232 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (SS) for 10 seconds
Number of subjects: 20
Study 25999434 — intervention group
Group type: EXPERIMENTAL
Intervention: (68)Ga-DOTA-exendin-4 PET/CT
Number of subjects: 5
Study 25999434 — intervention group
Group type: COMPARATOR
Intervention: (111)In-DOTA-exendin-4 SPECT/CT
Number of subjects: 5
Study 23666599 — intervention group
Group type: EXPERIMENTAL
Intervention: RAHelp online intervention with weekly telephone support
Number of subjects: 106
Study 23666599 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 106
Study 21858614 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of 0.75% ropivacaine (Group 5)
Number of subjects: 60
Study 21858614 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of 0.75% ropivacaine (Group 10)
Number of subjects: 60
Study 19726188 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE) as a countermeasure during 8 weeks of bed rest
Number of subjects: 12
Study 19726188 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise) during 8 weeks of bed rest
Number of subjects: 12
Study 17302069 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined Xuefu Capsule (RXC) for 3 months
Number of subjects: 38
Study 17302069 — intervention group
Group type: COMPARATOR
Intervention: Control group (Warfarin only)
Number of subjects: 38
Study 17302069 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined Xuefu Capsule (RXC)
Number of subjects: 38
Study 15472166 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin administration (850 mg twice daily for 6 months)
Number of subjects: 120
Study 15472166 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ovarian diathermy (LOD) with multivitamins
Number of subjects: 120
Study 10845352 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Music Therapy (MT)
Number of subjects: 32
Study 10845352 — intervention group
Group type: COMPARATOR
Intervention: Physical Therapy (PT)
Number of subjects: 32
Study 9105740 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoventricular streptokinase infusion (20,000 U/day for 96 hours)
Number of subjects: 12
Study 9105740 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with streptokinase)
Number of subjects: 12
Study 8472407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless THA
Number of subjects: 127
Study 8472407 — intervention group
Group type: COMPARATOR
Intervention: Cemented THA
Number of subjects: 127
Study 3102167 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin ointment applied 3-times daily for 4 to 10 days
Number of subjects: 200
Study 3102167 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (oral) in normal dosage for skin infections
Number of subjects: 200
Study 3102167 — intervention group
Group type: COMPARATOR
Intervention: Flucloxacillin (oral) in normal dosage for skin infections
Number of subjects: 200
Study 31021033 — intervention group
Group type: EXPERIMENTAL
Intervention: Pontine infarction
Number of subjects: 40
Study 31021033 — intervention group
Group type: EXPERIMENTAL
Intervention: Striato-capsular infarction
Number of subjects: 40
Study 29029237 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 220
Study 29029237 — intervention group
Group type: COMPARATOR
Intervention: No-CPAP
Number of subjects: 220
Study 25956171 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-drug ART (tenofovir+emtricitabine+efavirenz+raltegravir+maraviroc, n=18)
Number of subjects: 54
Study 25956171 — intervention group
Group type: COMPARATOR
Intervention: Three-drug ART (tenofovir+emtricitabine+efavirenz, n=18)
Number of subjects: 54
Study 23873255 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsional phacoemulsification
Number of subjects: 80
Study 23873255 — intervention group
Group type: COMPARATOR
Intervention: Conventional phacoemulsification
Number of subjects: 80
Study 23873255 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 21375852 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronate-iodine soaked gauze applied to wounds either daily or every other day depending on the amount of wound exudate.
Number of subjects: 14
Study 21375852 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronate-iodine
Number of subjects: 14
Study 18650064 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 74
Study 18650064 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage global scar area (GSA)
Number of subjects: 74
Study 18650064 — intervention group
Group type: EXPERIMENTAL
Intervention: GSA </= 18%
Number of subjects: 74
Study 18650064 — intervention group
Group type: EXPERIMENTAL
Intervention: End-diastolic wall thickness (EDWT) < 6 mm
Number of subjects: 74
Study 17302372 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (INDO) at a dosage of 1 mg/kg body weight, administered orally to CCoV-infected dogs.
Number of subjects: 1
Study 17302372 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1
Study 12890273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy treatment for 12 weeks
Number of subjects: 135
Study 10098804 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory
Number of subjects: 33
Study 8550780 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg esterified estrogen and 2.5 mg methyltestosterone (E+A)
Number of subjects: 2
Study 8550780 — intervention group
Group type: COMPARATOR
Intervention: 1.25 mg conjugated equine estrogen (CEE)
Number of subjects: 2
Study 8550780 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (E+A and CEE)
Number of subjects: 2
Study 8550780 — intervention group
Group type: EXPERIMENTAL
Intervention: E+A
Number of subjects: 2
Study 1909978 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a buserelin acetate 600 microgram/d plus hMG
Number of subjects: 157
Study 1909978 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a buserelin acetate 1,200 microgram/d plus hMG
Number of subjects: 157
Study 1909978 — intervention group
Group type: COMPARATOR
Intervention: hMG alone
Number of subjects: 157
Study 1909978 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a buserelin acetate
Number of subjects: 157
Study 6619040 — intervention group
Group type: EXPERIMENTAL
Intervention: ticarcillin (4.0 g every 6 h for 7 days)
Number of subjects: 18
Study 6619040 — intervention group
Group type: COMPARATOR
Intervention: mezlocillin (4.0 g every 6 h for 7 days)
Number of subjects: 18
Study 6619040 — intervention group
Group type: COMPARATOR
Intervention: placebo (4.0 g every 6 h for 7 days)
Number of subjects: 18